According to research reviewed by Gram, MAIT cells, a type of immune cell, appear to help drive artery plaque and inflammation. A 2026 study in Cardiovascular Research found these cells in higher numbers in human artery plaque, and mice without them had less plaque and smaller heart damage. The findings are early and mostly from animals.
Heart disease often starts when fatty deposits build up inside artery walls. A new study in Cardiovascular Research looked at a type of immune cell called MAIT cells and found that they collect in human artery plaque, where they appear to act in a more inflammatory, harmful way. In mice, removing MAIT cells reduced plaque buildup, lowered liver scarring, and shrank heart damage after a simulated heart attack, without changing blood cholesterol levels. The researchers also found that MAIT cells may boost the production of white blood cells called monocytes, which help drive artery inflammation. According to research reviewed by Gram, these findings point to MAIT cells as a possible new target for future heart disease treatments. The work is still early, however, and most of the evidence comes from mice, so it does not yet change how people should prevent or treat heart disease.
Key Statistics
A 2026 study published in Cardiovascular Research found that MAIT cells were significantly more common among immune T cells in human carotid artery plaques than in matched blood samples.
A 2026 mouse study in Cardiovascular Research found that mice lacking MAIT cells had less artery plaque, less liver scarring, and smaller heart damage after a simulated heart attack, without any change in cholesterol levels.
The Quick Take
- What they studied: Researchers wanted to know whether a specific type of immune cell, called MAIT cells, plays a role in clogged arteries and the heart damage that can follow.
- Who participated: The study used tissue samples from human carotid arteries (the large arteries in the neck) and blood from the same people, plus several groups of genetically modified mice fed a high-cholesterol diet. The abstract does not report the total number of participants or samples.
- Key finding: MAIT cells were more common in human artery plaque than in the blood of the same people. In mice, those without MAIT cells had less artery plaque, less liver scarring, and smaller heart damage after a simulated heart attack, even though their cholesterol levels did not change.
- What it means for you: This is early laboratory research, so it does not mean you should change your care based on it. The results do suggest that the immune system is a meaningful part of heart disease, which may lead to new treatments in the future. Proven steps like eating well, staying active, and managing cholesterol and blood pressure still matter most today.
The Research Details
The researchers first examined artery plaque removed from people with narrowing of the carotid arteries. They compared immune cells inside the plaque with immune cells from the blood of the same individuals. MAIT cells were identified using a special marker that binds to them, which allowed the team to count and study them. Cells were then sorted out and analyzed for the genetic activity they showed, which can reveal what the cells are doing.
Next, the team used mice. Some mice were bred to have higher numbers of MAIT cells, and they were fed a diet high in cholesterol to trigger artery plaque. The researchers tracked MAIT cells in the liver, the aorta (the main artery leaving the heart), and the bone marrow, where blood cells are made. They then compared these mice with mice that lacked MAIT cells.
To test how the effect worked, the team also blocked a receptor called CCR2, which controls how monocytes leave the bone marrow and travel through the body. When monocytes could not move this way, the effects of MAIT cells disappeared, which supports the idea that monocytes are the link between MAIT cells and artery inflammation.
Combining human tissue with mouse experiments allows researchers to check whether a finding in one setting also appears in the other. Seeing MAIT cells in human plaque shows the link is relevant to people, while the mouse work lets scientists change one factor at a time and observe the result. Blocking CCR2 was a particularly useful test because it helped show how MAIT cells cause harm rather than only showing that they are present.
The study was published in Cardiovascular Research, a well-respected journal in heart science, and it used several methods that support one another, including tissue analysis, genetic activity measurements, and targeted experiments. However, the abstract does not state the number of human or mouse samples, which makes it harder to judge how strong the statistics are. Mouse results do not always carry over to people, and the human part of the study compared plaque with blood rather than following patients over time. Independent studies will be needed to confirm these results.
What the Results Show
MAIT cells were significantly more common among immune T cells in human carotid artery plaques than in the blood of the same people. The cells inside plaque looked activated and worn out, and their genetic activity pointed to increased inflammation, stress responses, and signals that attract other immune cells. In other words, the MAIT cells in plaque appeared to be working in a way that could worsen artery damage.
In the mouse experiments, mice with higher MAIT cell numbers showed more MAIT cells collecting in the liver and aorta when fed a high-cholesterol diet. Their bone marrow MAIT cells also appeared activated, and their genetic activity suggested that the bone marrow was producing more immune cells. This points to MAIT cells influencing the immune system from its source.
When MAIT cells were absent, mice had less atherosclerosis (artery plaque buildup), less liver fibrosis (scarring), and smaller heart damage after a blocked coronary artery was tied off to mimic a heart attack. Importantly, these benefits occurred without any change in plasma cholesterol, which suggests that MAIT cells affect heart disease through inflammation rather than through blood fat levels.
The researchers also found fewer myeloid progenitors (early cells that become white blood cells) in the bone marrow, fewer monocytes in the bone marrow and blood, and less macrophage buildup inside plaques when MAIT cells were missing. Blocking monocyte movement with CCR2 deficiency removed the MAIT-related effects, which the authors used to support a monocyte-driven mechanism.
The study suggests that MAIT cells may do more than fight microbes. They appear to help control how many monocytes the body makes and releases, which may matter in many inflammatory conditions. The reduced liver scarring in mice without MAIT cells also hints that these cells may influence organs beyond the heart and blood vessels. These links are interesting, but they still need confirmation in human studies.
Scientists have long known that inflammation drives atherosclerosis, and monocytes and macrophages are well-established players in artery plaque. This study adds a new piece by suggesting that MAIT cells, which were previously studied mainly for their role in fighting bacteria, may help set the stage for those inflammatory cells. It builds on earlier work linking immune cells to heart disease, but the MAIT-specific role is newer and less established.
Most of the evidence comes from mice, and mice do not develop heart disease exactly as people do. The human portion examined plaque from people who already had artery narrowing, so it cannot show whether MAIT cells cause plaque in the first place. The abstract does not report sample sizes or detailed statistics, which makes the strength of each result hard to judge. The researchers also did not test whether medicines targeting MAIT cells are safe or effective, so the idea of MAIT-based treatments remains a hypothesis.
The Bottom Line
No changes to heart disease prevention or treatment are recommended based on this study alone. Confidence that MAIT cells contribute to artery inflammation is moderate, based on consistent results across human tissue and several mouse experiments. Confidence that targeting MAIT cells would help people is currently low, because no human trials have been reported. Established steps such as controlling LDL cholesterol, blood pressure, and blood sugar, not smoking, and staying physically active remain the evidence-based approach.
People with a family history of heart disease, clogged arteries, or previous heart attacks may find this research encouraging because it points toward future treatments. Doctors and researchers working on cardiovascular inflammation will likely find it especially useful. People who are generally healthy do not need to act on these findings, and no one should stop or change any prescribed medicine because of this study.
Findings from laboratory and mouse research usually take many years to reach patients. Any treatment aimed at MAIT cells would first need testing for safety in people, which often takes five to ten years or more. In the meantime, the benefits you can get now come from proven habits and medical care, which can reduce heart risk within weeks to months.
Frequently Asked Questions
What are MAIT cells and do they affect heart disease?
MAIT cells are a type of immune cell that normally helps fight bacteria. A 2026 study in Cardiovascular Research suggests they may also worsen artery inflammation and plaque buildup, though this has been shown mainly in mice and in human tissue samples.
Can MAIT cells be targeted to treat clogged arteries?
Researchers have proposed MAIT cells as a possible treatment target for atherosclerosis, but no treatment has been tested in people yet. Current proven approaches include managing LDL cholesterol, blood pressure, and blood sugar, along with regular physical activity.
Does this study mean I should change my heart medicine?
No. The study was laboratory research using human tissue samples and mice, and it did not test any new treatment in patients. Anyone taking heart medication should continue following their doctor’s advice and talk with them before making any changes.
How did the study show that monocytes play a role?
Researchers blocked CCR2, a receptor that helps monocytes leave the bone marrow and travel through the body. When monocytes could not move this way, the effects linked to MAIT cells disappeared, which supports monocytes as a key part of the process.
Want to Apply This Research?
- Track your LDL cholesterol, blood pressure, and fasting blood sugar using results from your doctor or home blood pressure monitor, and log them in the app once per month. Also record your weekly minutes of moderate activity, aiming for at least 150 minutes. These measures are proven indicators of heart risk and are easy to monitor consistently.
- Set a simple daily goal, such as a 20-minute walk after one meal, and log it in the app. Add one heart-healthy change each week, like swapping fried snacks for vegetables, nuts, or whole grains. Use the app’s reminders to check in on these habits, since steady routines are more useful than occasional big efforts.
- Review your tracked numbers every three months and share trends with your doctor at regular checkups. Update your habit log weekly and look for patterns over six to twelve months. Keep an eye on new research in this area, but rely on your care team for decisions about your heart health.
This article summarizes early laboratory and animal research on immune cells and artery disease. The findings have not been tested as treatments in people and should not be used to diagnose, treat, or prevent any condition. Talk with your doctor before making changes to your diet, exercise, or medications, especially if you have heart disease or risk factors for it.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.